[en] CI-943 is a new drug candidate with antipsychotic-like activity in a variety of behavioural tests in rodents and primates, but without any affinity for brain dopamine receptors. CI-943 does not cause dystonia in monkeys, a predictive symptom of extrapyramidal side effects (EPS). Its mechanism of action remains unclear. Neurotensin (NT) concentration in nucleus accumbens and caudate is increased by CI-943; this may be associated with its antipsychotic effect. Indeed various observations suggest that the clinical action of antipsychotic drugs may at least be partially mediated by some neuropeptides. Various actions of neurotensin are reviewed. The hypothesis on the role of neurotensin represents a new strategy in the development of pharmacological tools for the treatment of schizophrenia.
Liégeois, Jean-François ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique
Bonaventure, P.
Delarge, J.
Damas, Jacques ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Language :
English
Title :
Antipsychotics and Neuropeptides: The Atypical Profile of Ci-943 and Its Relationship to Neurotensin
Abou-Gharbia, Moyer (1990) Novel antipsychotic agents. Annual reports in medicinal chemistry , 8th edn., J.A. Bristl, J. MacCall, Academic Press, San Diego; 25:1-10.
Adachi, Kalivas, Schenk (1990) Neurotensin binding to dopamine. J. Neurochem. 54:1321-1328.
Agnati, Fuxe, Benfenati, Battistini (1983) Neurotensin in vitro markedly reduces the affinity in subcortical limbic 3H-N-propylnorapomorphine binding sites. Acta Physiol. Scand. 119:459-461.
Agnati, Fuxe, Battistini, Giardino, Benfenati, Martire, Ruggeri (1985) Further evidence for the existence of interactions between receptors for dopamine and neurotensin. Dopamine reduces the affinity and increases the number of [3H]neurotensin binding sites in the subcortical limbic forebrain in the rat. Acta Physiol. Scand. 124:125-128.
Andèn, Stock (1973) Effects of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system. Journal of Pharmacy and Pharmacology 25:346-348.
Angst, Jaenicke, Padrutt, Scharfetter (1971) Ergebnisse eines Doppelblindversuches von HF 1854 (8-chlor-11-(4-methyl-1-piperazinyl)-5H-dibenzo-(be)-14-diazepine) im Vergleich su Levomepromazin. Pharmacopsychiatry 4:192-200.
Baldessarini (1990) Drugs and the treatment of psychiatric disorders. The pharmacological basis of therapeutics , L.S. Goodman, A. Gilman, R.W. Rall, A.S. Nies, P. Taylor, 8th edn., Pergamon Press, New York; 383-435.
Baldino, Davis, Wolfson (1985) Structure-activity studies with carboxy- and amino-terminal fragments of neurotensin on hypothalamic neurons in vitro. Brain Res. 342:266-272.
Beaudet, Mazella, Nouel, Chabry, Castel, Laduron, Kitabgi, Faure (1994) Internalization and intracellular mobilization of Neurotensin in neuronal cells. Biochem. Pharmacol. 47:43-52.
Blaha, Phillips (1992) Pharmacological evidence for common mechanisms underlying the effects of neurotensin and neuroleptics on in vivo dopamine efflux in the rat nucleus accumbens. Neuroscience 49:867-877.
Bruhwyler, Liégeois, Chleide, Rogister, Damas, Delarge, Mercier (1992) Comparative study of typical neuroleptics, clozapine and new synthesized clozapine-analogues: correlations between neurochemistry and behaviour. Behav. Pharmacol. 3:567-579.
.
Bunney, Walters, Roth, Aghajanian (1973) Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity. J. Pharm. Exp. Ther. 185:560-571.
Cain, Abramson, Nemeroff (1988) Neurotensin stimulates the phosphorylation of caudate nucleus synaptosomal proteins. Ann. N.Y. Acad. Sci. 537:488-490.
Canton, Verrièle, Colpaert (1990) Binding of typical and atypical antipsychotics to 5-HT1C and 5-HT2 sites: clozapine potently interacts with 5-HT1C sites. Eur. J. Pharmacol. 191:93-96.
Carraway, Leeman (1973) The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J. Biol. Chem. 248:6854-6861.
Castel, Morino, Hokfelt (1993) Modulation of the Neurotensin striato-nigral pathway by D1 receptors. Neuroreport 5:281-284.
Castel, Beaudet, Laduron (1994) Retrograde axonal transport of neurotensin in rat nigrostriatal dopaminergic neurons. Modulation during ageing and possible physiological role. Biochem. Pharmacol. 47:53-62.
Chiodo, Bunney (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopamine neurons. J. Neurosci. 3:1607-1619.
Chiodo, Bunney (1985) Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J. Neurosci. 9:2539-2544.
Clissold, Pontecorvo, Jones, Abreu, Karbon, Erickson, Natalie, Borosky, Hartman, Mansbach, Balster, Ferkany, Enna (1993) NPC 16377, a potent and selective σ-ligand. II. Behavioral and neuroprotective profile. J. Pharmacol. Exp. Ther. 265:876-886.
de Quidt, Emson (1983) Neurotensin facilitates dopamine release in vitro from striatal slices. Brain Res. 274:376-380.
Deutch, Moghaddam, Innis, Krystal, Aghajanian, Bunney, Charney (1991) Mechanisms of action of atypical antipsychotic drugs Implications for novel therapeutic strategies for schizophrenia. Schizophrenia Research 4:121-156.
DeWald, Lobbestael, Butler (1977) Pyrazolodiazepines. 2. 4-Aryl-1,3-dialkyl-6,8-dihydropyrazolo[3,4-e][1,4]-diazepin-7(1H)-ones as antianxiety and anticonvulsant agents. J. Med. Chem. 20:1562-1569.
DeWald, Lobbestael, Poschel (1981) Pyrazolodiazepines. 3. 4-Aryl-1,6,7,8-tetrahydro-1,3-dialkylpyrazolo[3,4-e][1,4]diazepines as antidepressant agents. J. Med. Chem. 24:982-987.
DeWald, Beeson, Hershenson, Wise, Downs, heffner, Coughenour, Pugsley (1988) Synthesis and potential antipsychotic activity of 1H-imidazol[1,2-c]pyrazolo[3,4-e]pyrimidines. J. Med. Chem. 31:454-461.
Duff Davis, Nemeroff (1988) Neurotensin, dopamine, and schizophrenia. Receptors and ligands in psychiatry , A.K. Sen, T. Lee, Cambridge University Press, Cambridge; 167-186.
Ellenbroek (1993) Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmac. Ther. 57:1-78.
Fuxe, Von Euler, Agnati, Merlo Pich, O'Connor, Tanganelli, Li, Tinner, Cintra, Carani, Benfenati (1992) Intramembrane interactions between neurotensin receptors and dopamine D2 receptors as a major mechanism for the neuroleptic-like action of neurotensin. Ann. N.Y. Acad. Sci. 668:186-204.
Garver, Bissette, Yao, Nemeroff (1991) Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients. Am. J. Psychiatry 148:484-488.
Gilbert, Richelson (1984) Neurotensin stimulates the formation of cyclic GMP in murine blastoma clone NIE-115. Eur. J. Pharmacol. 99:245-246.
Goedert (1984) Neurotensin, a status report. Trends Neurosci. 7:3-5.
Goedert, Pinnock, Downes, Mantyh, Emson (1984) Neurotensin stimulates inositol phospholipid hydrolysis in rat brain slices. Brain Res. 323:193-197.
Grace, Bunney (1986) Induction of depolarization block in midbrain dopamin neurons by repeated administration of haloperidol: analysis using in vivo intracellular recording. J. Pharmacol. Exp. Ther. 238:1092-1100.
Grohmann, Schmidt, Spieb-Kiefver, Rüther (1989) Agranulocytosis and significant leucopenia with neuroleptic drugs: results from the AMÜP Program. Psychopharmacology 99:S109-S112.
Gross, Langner (1966) Das Wirkungsprofil eines chemisch neuartigen Breitbandneuroleptikums der Dibenzodiazepin-gruppe. Wien. Med. Wochenschr. 116:814-816.
Gully, Canton, Boigegrain, Jeanjean, Molimard, Poncelet, Gueudet, Heaulme, Leyris, Brouard, Pelaprat, Labbé-Jullié, Mazella, Soubrié, Maffrand, Rostène, Kitabgi, Le Fur (1993) Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc. Natl. Acad. Sci. U.S.A. , 3rd ed.; 90:65-69.
Hanson, Witoslawski, Campbell, Itkin (1966) Estimation of relative antiavoidance activity of depressant drugs in squirrel monkeys. Arch. Int. Pharmacodyn. Ther. 161:7.
Heffner, Downs, Meltzer, Wiley, Williams (1989) CI-943, a potential antipsychotic agent. I. Preclinical behavioral effects. J. Pharmacol. Exp. Ther. 251:105-112.
Hippius (1989) The history of clozapine. Psychopharmacology (Berlin) 99:S3-S5.
Hünziker, Künzle, Schmutz (1963) Über ein 5-Stellung basich substituierte 5-H-Dibenzo[be]-14-diazepine. Helvetica Chimica Acta 46:2337-2346.
Jolicoeur, Gagne, Rivest, Drumheller, St Pierre (1993) Atypical neuroleptic-like behavioural effects of neurotensin. Brain Res. Bull. 32:487-491.
Jordan (1989) Peptides. Neurotransmitters and drugs disease , R.A. Webster, C.C. Jordan, Blackwell Scientific Publications, Oxford; 211-264.
Karbon, Abreu, Erickson, Kaiser, Natalie, Clissold, Borosky, Bailey, Martin, Pontecorvo, Enna, Ferkany (1993) NPC 16377, a potent and selective σ-ligand. I. Receptor binding, neurochemical and neuroendocrine profile. J. Pharmacol. Exp. Ther. 265:866-875.
Kasckow, Nemeroff (1991) The neurobiology of neurotensin: focus on NT-DA interactions. Regul. Pept. 36:153-164.
Kimes, Raymon, Meltzer, Heffner, London (1991) Cerebral metabolic effects of CI-943 (8-ethyl-7,8-dihydro-1,3,5-trimethyl-1H-imidazol[1,2-c]pyrazolo[3,4-e]pyrimidine), a potential antipsychotic drug. Drug. Dev. Res. 24:29-39.
Kobayashi, Brown, Vale (1977) Regional distribution of neurotensin and somatostatin in rat brain. Brain Res. 126:584-588.
Koob, Riley, Christine Smith, Robbins (1978) Effects of 6-hydroxydopamine lesions of the nucleus accumbens septi and olfactory tubercle on feeding, locomotor activity, and amphetamine anorexia in the rat. J. Comp. Physiol. Psychol. 92:917-927.
Levant, Nemeroff (1988) The psychobiology of neurotensin. Current topics in neuroendocrinology , 3rd ed., D. Ganten, D. Pfaff, Springer-Verlag, Berlin; 8:231-262.
Levant, Bissette, Duff Davis, Heffner, Nemeroff (1991) Effects of CI-943, a potential antipsychotic drug, and haloperidol on regional brain neurotensin concentrations. Synapse 9:225-230.
Leysen, Gommeren, Eens, de Chaffoy de Courcelles, Stoof, Janssen (1988) Biochemical profile of risperidone, a new antipsychotic. J. Pharmacol. Exp. Ther. 247:661-670.
Lieberman, Johns, Kane, Rai, Pisciotta, Saltz, Howard (1988) Clozapine-induced agranulocytosis non-cross reactivity with other psychotropic drugs. J. Clin. Psychiatry 49:271-277.
Liégeois, Bruhwyler, Damas, Nguyen, Chleide, Mercier, Rogister, Delarge (1993) New pyridobenzodiazepine derivatives as potential antipsychotics synthesis and neurochemical study. Journal of Medicinal Chemistry 36:2107-2114.
Liégeois, Rogister, Bruhwyler, Damas, Nguyen, Inarejos, Chleide, Mercier, Delarge (1994) Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents synthesis and neurochemical study. Journal of Medicinal Chemistry 37:519-525.
Lindstrom, Widerlov, Bissette, Nemeroff (1988) Reduced CSF neurotensin concentration in drug-free schizophrenic patients. Schizophrenia Research 1:55-59.
Lowe, Seeger, Vinick (1988) Atypical antipsychotics — Recent findings and new perspectives. Med. Res. Rev. 8:475-497.
Mazella, Poustis, Labbé, Checler, Kitabgi, Granier, Van Rietschoten, Vincent (1983) [monoiodo-Trp11]neurotensin, a highly radioactive ligand of neurotensin receptors. Preparation, biological activity and binding properties to rat brain synaptic membranes. J. Biol. Chem. 258:3476-3481.
Megens, Niemegeers, Awouters (1992) Behavioral disinhibition and depression in amphetaminized rats: A comparison of risperidone, ocaperidone and haloperidol. J. Pharmacol. Exp. Ther. 260:160-167.
Meltzer, Fang (1976) The effect of neuroleptics on serum prolactin levels in schizophrenic patients. Archives of General Psychiatry 30:279-286.
Meltzer, Fang, Fessler, Simonovic, Stanisic (1977) Neuroleptic-stimulated prolactin secretion in the rat as an animal model of biological psychiatry: 1. Comparison with antipsychotic activity. Animal models in psychiatry and neurology , I. Hanin, E. Usdin, Pergamon Press, Oxford; 443-454.
Meltzer, Matsubara, Lee (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin-2 pKi values. J. Pharmacol. Exp. Ther. 251:238-246.
Meltzer, Christoffersen, Heffner, Freeman, Chiodo (1989) CI-943, a potential antipsychotic agent. III. Evaluation of effects on dopamine neuronal activity. J. Pharmacol. Exp. Ther. 251:123-130.
Moore, Tye, Axton, Risius (1992) Behavioral pharmacology of olanzapine, a novel atypical antipsychotic agent. J. Pharmacol. Exp. Ther. 262:545-551.
Moore, Rees, Sanger, Tye (1994) Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav. Pharmacol. 5:196-202.
Myers, Levant, Bissette, Nemeroff (1992) Specificity of the increase in neurotensin concentrations after antipsychotic drug treatment. Brain Res. 575:325-328.
Nemeroff, Luttinger, Prange (1980) Neurotensin: central nervous system effects of a neuropeptide. Trends Neurosci. 3:212-215.
Nemeroff, Levant, Myers, Bissette (1992) Neurotensin, antipsychotic drugs, and schizophrenia. Basic and clinical studies. Ann. N.Y. Acad. Sci. 668:146-156.
O'Connor, Tanganelli, Ungerstedt, Fuxe (1992) The effects of neurotensin on GABA and acetylcholine release in the dorsal striatum of the rat: an in vivo microdialysis study. Brain Res. 573:209-216.
Peroutka, Snyder (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic and histamine receptors to clinical potency. Am. J. Psychiatry 137:1518-1522.
Perregaard, Andersen, Hyttel, Sanchez (1992) Selective, centrally acting serotonin 5-HT2 antagonists. 1. 2- and 6-substituted-1-phenyl-3-(4-piperidinyl)-1H-indoles. J. Med. Chem. 35:4813-4822.
Petit, Lepine, Lesieur (1979) Chronologie des effets extrapyramidaux des neuroleptiques et système dopaminergique nigro-striatal. L'Encéphale 5:297-316.
Peuskens, Claus, De Cuyper, Bollen, Eneman, Wilms (1989) Risperidone: A new approach in the treatment of schizophrenia. Abstr. VIII World Congress Psychiatr. , Athens, Greece, Excerpta Medica International Congress Series 899, Amsterdam; 347.
Pisciotta (1990) Drug induced agranulocytosis peripheral destruction of polymorphonuclear leukocytes and their marrow precursors. Blood Rev. 4:226-237.
Pugsley, Coughenour, Myers, Shih, Courtland, Berghoff, Stewart (1989) CI-943, a potential antipsychotic agent. II. Neurochemical effects. J. Pharmacol. Exp. Ther. 251:113-122.
Richelson, Nelson (1984) Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur. J. Pharmacol. 103:197-204.
Sadoul, Mazella, Amar, Kitabgi, Vincent (1984) Preparation of neurotensin selectively iodinated on the tyrosine-3 residue. Biological activity and binding properties on mammalian neurotensin receptors. Biochem. Biophys. Res. Commun. 120:812-819.
Sanz, Esposito, Mora (1993) Effects of neurotensin on the release of glutamic acid in the prefrontal cortex and striatum of the rat. Neuroreport 4:1194-1196.
Schorderet, Calalca (1988) Neuroleptiques (antipsychotiques). Pharmacologie. Des concepts fondamentaux aux applications thérapeutiques , M. Schorderet, Edition Slatkine, Genève; 369-384.
Schotte, Leysin, Laduron (1986) Evidence for a displaceable nonspecific [3H]neurotensin binding site in rat brain. Naunyn-Schmiedeberg's Archives of Pharmacology 333:400-405.
Shi, Bunney (1992) Actions of neurotensin: a review of the electrophysiological studies. Ann. N.Y. Acad. Sci. 668:129-145.
Sokoloff, Giros, Martres, Bouthenet, Schwartz (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146-151.
Stowe, Bissette, Nemeroff (1991) Neurotensin-dopamine interactions: relevance to schizophrenia and the actions of antipsychotic drugs. Yakubutsu-Seishin-Kodo 11:49-59.
Tamminga, Gerlach (1987) New neuroleptics and experimental antipsychotics in schizophrenia. Psychopharmacology: The third generation of progress , H.Y. Meltzer, Raven Press, New York; 1129-1140.
Tanaka, Masu, Nakanishi (1990) Structure and functional expression of the cloned rat neurotensin receptor. Neuron 4:847-854.
Tanganelli, Li, Ferraro, Von Euler, O'Connor, Bianchi, Beani, Fuxe (1993) Neurotensin and cholecystokinin octapeptide control synergistically DA release and dopamine D2 receptor affinity in rat neostriatum. Eur. J. Pharmacol. 23:159-160.
Torocsik, Rakovska, Gorcs, Vizi (1993) Effect of neurotensin and immunoneutralization with anti-neurotensin-serum on dopaminergic-cholinergic interaction in the striatum. Brain Res. 612:306-312.
Tricklebank, Bristow, Hutson (1992) Alternative approaches to the discovery of novel antipsychotic agents. Progress in drug research , E. Jucker, 3rd ed., Fortschritte der Arzneimittel forschung, Birkhäuser Verlag, Basel, Boston, Berlin; 38:299-336.
Turner, James-Kracke, Camden (1990) Regulation of neurotensin receptor and intracellular calcium in HT29 cells. J. Pharmacol. Exp. Ther. 253:1049-1056.
Uhl, Snyder (1977) Regional and subcellular distribution of brain neurotensin. Life Sci. 19:1827-1832.
Van Tol, Bunzow, Guan, Sunahara, Seeman, Niznik, Civelli (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610-614.
Vincent (1992) Neurotensin receptors. Binding properties, transduction mechanisms, and purification. Ann. N.Y. Acad. Sci. 668:90-100.
Waldmeier, Delini-Stula (1979) Serotonin-dopamine interactions in the nigro-striatal system. Eur. J. Pharmacol. 55:363-373.
Watling, Beer, Stanton, Newberry (1990) Interaction of the atypical neuroleptic clozapine with 5-HT3 receptors in the cerebral cortex and superior cervical ganglion of the rat. Eur. J. Pharmacol. 182:465-472.
White, Wang (1983) Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221:1054-1057.
Widerlov, Linstrom, Besev, Manberg, Nemeroff, Breese, Kizer, Prange (1982) Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment. Am. J. Psychiatry 139:1122-1126.
Wise, Heffner (1989) The potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines. Drugs Future 14:1073-1082.
Wolf, Villeneuve (1991) Les effets indésirables des neuroleptiques. L'Encéphale 16:111-124.